Vaishali Pharma Board of Directors

Get the latest insights into the leadership at Vaishali Pharma. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Atul Arvind Vasani Chairman & Managing Director
Mr. Dewansh Ajay Vasani Executive Director & CFO
Mrs. Jagruti Atul Vasani Whole Time Director
Mr. Manish Bhagwandas Ved Ind. Non-Executive Director
Mr. Pratik Vikram Jakhelia Ind. Non-Executive Director
Mr. Bhaveshkumar Upadhyay Non Exe.Non Ind.Director

Vaishali Pharma Share price

VAISHALI

9.69

0.13 (1.36%)
Last updated on 14 Nov, 2025 | 15:29 IST
BUYSELL
Today's High

9.79

Today's Low

9.52

52 Week Low

9.00

52 Week High

20.41

The current prices are delayed, login to your account for live prices

Vaishali Pharma FAQs

The board at Vaishali Pharma consists of experienced professionals, including Mr. Atul Arvind Vasani , Mr. Dewansh Ajay Vasani , and others, overseeing the company’s strategic and corporate governance.

Directors at Vaishali Pharma are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Atul Arvind Vasani is the current chairman at Vaishali Pharma.

Executive directors at Vaishali Pharma are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Vaishali Pharma adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Vaishali Pharma, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.